Table 1.
Minimal Inhibitory Concentration (MIC) and susceptibility profile of C.krusei clinical isolates.
Table 2.
Primers used in this study.
Table 3.
ERG11 gene point mutations in C.krusei clinical isolates.
Table 4.
ABC1, ABC2 and ERG11 genes relative level of mRNA expression in C.krusei clinical isolates.
Fig 1.
ABC1 relative gene expression levels in three groups of C.krusei clinical isolates.
(A) Relative levels of ABC1 mRNA in all the C.krusei clinical isolates. ABC1 gene expression levels was quantified and normalized relative to the housekeeping gene, ACT1; S, itraconazole-susceptible; SDD, itraconazole-susceptible dose dependent; R, itraconazole-resistant. (B) Log10+3 fold increase of gene expression levels in three groups. (NS, no significance in SDD compared with S; *P<0.05 in R with S; **P<0.01 in R with SDD).
Fig 2.
ABC2 relative gene expression levels in three groups of C.krusei clinical isolates.
(A) Relative levels of ABC2 mRNA in all the C.krusei clinical isolates. ABC2 gene expression levels was quantified and normalized relative to the housekeeping gene, ACT1; S, itraconazole-susceptible; SDD, itraconazole-susceptible dose dependent; R, itraconazole-resistant. (B) Log10+3 fold increase of gene expression levels in three groups. (*P<0.05 in R compared with SDD; **P<0.01 in SDD with S; ***P<0.001 in R with S).
Fig 3.
ERG11 relative gene expression levels in three groups of C.krusei clinical isolates.
(A) Relative levels of ERG11 mRNA in all the C.krusei clinical isolates. ERG11 gene expression levels was quantified and normalized relative to the housekeeping gene, ACT1; S, itraconazole-susceptible; SDD, itraconazole-susceptible dose dependent; R, itraconazole-resistant. (B) Log10+3 fold increase of gene expression levels in three groups. (NS, no significance in SDD compared with S; *P<0.05 in R with SDD; **P<0.01 in R with S).